2. Search Result
Search Result
Results for "

myocardial contractility

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123268A
    Ro 363 hydrochloride
    2 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease
    Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .
    Ro 363 hydrochloride
  • HY-106844
    EMD 53998

    		Phosphodiesterase (PDE) Cardiovascular Disease
    EMD 53998 is a cardiotonic agent that increases myocardial contractility as an inhibitor for phosphodiesterase III (PDE III) and a calcium sensitizer. EMD 53998 increases myocardial contractility, reduces energy consumption and the risk of inducing arrhythmias .
    EMD 53998
  • HY-106577
    Cibenzoline

    Cifenline; Ro 22-7796

    		 Potassium Channel Cardiovascular Disease
    Cibenzoline is a potent inhibitor of KATP channel with directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline is a class Ia antiarrhythmic agent. Cibenzoline has little anticholinergic activity. Cibenzoline markedly attenuate LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for the research of hypertrophic obstructive cardiomyopathy .
    Cibenzoline
  • HY-106045
    Imazodan

    CI 914 free base

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Imazodan is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator .
    Imazodan
  • HY-106844A
    (+)-EMD 57033

    		Others Cardiovascular Disease
    (+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca 2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .
    (+)-EMD 57033
  • HY-123268
    Ro 363

    		Adrenergic Receptor Cardiovascular Disease
    Ro 363, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .
    Ro 363
  • HY-106577R
    Cibenzoline (Standard)

    		Potassium Channel Cardiovascular Disease
    Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a potent inhibitor of KATP channel with directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline is a class Ia antiarrhythmic agent. Cibenzoline has little anticholinergic activity. Cibenzoline markedly attenuate LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for the research of hypertrophic obstructive cardiomyopathy .
    Cibenzoline (Standard)
  • HY-106045A
    Imazodan hydrochloride

    CI 914

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Imazodan hydrochloride is the hydrochloride form of Imazodan (HY-106045). Imazodan hydrochloride is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan hydrochloride serves also as a peripheral vasodilator .
    Imazodan hydrochloride
  • HY-120926
    BBR 2160

    		Others Others
    BBR 2160 is a compound with cardiac electrophysiological effects and is a dihydropyridine calcium antagonist that can reduce myocardial contractility and action potential duration and has calcium antagonist properties.
    BBR 2160
  • HY-118833
    RAC 109

    		Others Cardiovascular Disease
    RAC 109 is a local anesthetic. RAC 109 reduces ventricular conduction velocity and myocardial contractility in rabbits in a stereospecific manner (EC50=30 μM) .
    RAC 109
  • HY-108991
    T-0509

    (-)-T-0509

    		 Adrenergic Receptor Cardiovascular Disease
    T-0509 ((-)-T-0509) is a selective full agonist of the β1 receptor. T-0509 activates the cAMP signaling pathway through the β1 receptor and enhances myocardial contractility .
    T-0509
  • HY-B1233
    Octodrine

    2-Amino-6-methylheptane; 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine

    		 Dopamine Receptor Others
    Octodrine (2-Amino-6-methylheptane) is a central nervous stimulant that increases the uptake of dopamine and noradrenaline. Octodrine is found to increase the pain threshold, cardiac rate (positive chronotropic effect) and myocardial contractility (positive inotropic effect) .
    Octodrine
  • HY-B1233A
    Octodrine hydrochloride

    2-Amino-6-methylheptane hydrochloride; 1,5-Dimethylhexylamine hydrochloride; 6-Methyl-2-heptylamine hydrochloride

    		 Dopamine Receptor Neurological Disease
    Octodrine (2-Amino-6-methylheptane) is a central nervous activator that increases the uptake of dopamine and noradrenaline. Octodrine is found to increase the pain threshold, cardiac rate (positive chronotropic effect) and myocardial contractility (positive inotropic effect) .
    Octodrine hydrochloride
  • HY-117181
    UK-1745

    		Phosphodiesterase (PDE) Adrenergic Receptor Cardiovascular Disease
    UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .
    UK-1745
  • HY-B0204B
    (-)-Pimobendan

    (-)-UD-CG115

    		 Others Cardiovascular Disease
    (-)-Pimobedan is an isomer of pimobedan. It has the property of stereoselective partitioning or distribution into erythrocytes. The clearance of (-)-pimobedan from erythrocytes is significantly lower than that of (+)-pimobedan, which is entirely due to its stereoselective distribution into erythrocytes. This stereoselective property of (-)-pimobedan may explain the phenomenon previously reported that it produces a 1.5-fold greater contractile force than the (+)-isomer in detergent-treated myocardial specimens of guinea pigs and dogs. These properties suggest that (-)-pimobedan may have unique advantages in terms of in vivo distribution and pharmacological action, which may have important implications for its clinical use.
    (-)-Pimobendan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: